Conditions: Type 2 Diabetes
Keywords: DPP-4 inhibitors HbA1c Incretins
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 570
Healthy volunteers: no

Brief summary:
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated with metformin in addition to diet and exercise.

Detailed description:

Arms:
arm 1: Metformin + Saxagliptin arm 2: Metformin + Placebo

Interventions: intervention 1: Saxagliptin intervention 2: Placebo intervention 3: Metformin
Intervention descriptions: intervention 1: Oral tablet, once daily for 24 weeks intervention 2: oral tablet, once daily for 24 weeks intervention 3: oral tablet, once daily for 24 weeks

Protocol document: